Neuro-oncology clinical trials: Promise and pitfalls

Annals of Oncology

Volumn 12, Issue 2, 2001, Pages 149-150

  Gilbert, M R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOSTATIC AGENT; RADIOSENSITIZING AGENT; TEMOZOLOMIDE;

BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; BRAIN CANCER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; EDITORIAL; GLIOBLASTOMA; GLIOMA; HUMAN; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; TUMOR RECURRENCE;

EID: 0035106858     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a000239     Document Type: Editorial

References (17)

1. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
2. Role of radiosurgery in the management of central nervous system metastases
3. The fallacy of the localized supratentorial malignant glioma
4. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study
5. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
6. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases
7. Temozolomide and treatment of malignant glioma
8. Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions
9. Increased 9-amino-camptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The new approaches the brain tumor therapy
10. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials
11. Response criteria for phase II studies of supratentorial malignant glioma
12. Response and progression in recurrent malignant glioma
13. Prognosis of intracranial germ-cell tumours: Effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16)
14. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases form breast carcinoma, non-small-cell lung carcinoma or malignant melanoma
15. Primary chemotherapy of brain metastases in small-cell lung cancer
16. NABYC 98-03: Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant gliomas
17. A phase II study of temozolomide plus marimastat for recurrent glioblastoma multiforme